---
title: "Alumis and Acelyrin to merge in all-stock deal"
date: "2025-02-07 14:47:46"
summary: "Alumis (ALUM) shares plunged ~17% in the premarket on Friday after the immunology-focused biopharma agreed to merge with its California-based rival Acelyrin (NASDAQ:SLRN) in an all-stock transaction. Acelyrin (NASDAQ:SLRN) shares traded ~4% higher in reaction. Per the deal terms, Acelyrin (NASDAQ:SLRN) shareholders are expected to receive 0.4274 shares of Alumis..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1347295696/image_1347295696.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Alumis (ALUM) shares plunged ~17% in the premarket on Friday after the immunology-focused biopharma agreed to merge with its California-based rival Acelyrin (NASDAQ:[SLRN](https://seekingalpha.com/symbol/SLRN "Acelyrin, Inc.")) in an all-stock transaction. Acelyrin (NASDAQ:[SLRN](https://seekingalpha.com/symbol/SLRN "Acelyrin, Inc.")) shares traded ~4% higher in reaction.

Per the deal terms, Acelyrin (NASDAQ:[SLRN](https://seekingalpha.com/symbol/SLRN "Acelyrin, Inc.")) shareholders are expected to receive 0.4274 shares of Alumis (NASDAQ:[ALMS](https://seekingalpha.com/symbol/ALMS "Alumis Inc.")) common stock for each share of SLRN common stock they own, and they will own roughly 45% of the combined entity, while Alumis (NASDAQ:[ALMS](https://seekingalpha.com/symbol/ALMS "Alumis Inc.")) shareholders will own the rest.

The combined company, led by the Alumis (NASDAQ:[ALMS](https://seekingalpha.com/symbol/ALMS "Alumis Inc.")) existing executive team, will operate under the Alumis name from its headquarters in South San Francisco. With approximately $737M of pro forma cash as of 2024 year-end, the new entity is expected to have a cash runway into 2027.

The companies said their shareholders, owning about 62% and 24% of Alumis ([ALMS](https://seekingalpha.com/symbol/ALMS "Alumis Inc.")) common stock and Acelyrin ([SLRN](https://seekingalpha.com/symbol/SLRN "Acelyrin, Inc.")) common stock, respectively, have signed voting agreements in support of the deal, which is expected [to close in Q2 2025.](https://seekingalpha.com/pr/19995041-alumis-and-acelyrin-to-merge-creating-a-late-stage-clinical-biopharma-company-dedicated-to)

[seekalpha](https://seekingalpha.com/news/4405040-alumis-stock-falls-merger-deal-acelyrin)
